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APHP, Paris, FranceAbstractHuman adenovirus (HAdV) infections constitute a major cause of morbidity in paediatric haematopoietic stem cell transplant (HSCT)
patients. New antiviral treatments offer promising perspectives. However, it remains challenging to identify patients at risk for
disseminated infection, and who should receive early antiviral intervention. We conducted a longitudinal study of allogeneic HSCT
recipients, including weekly HAdV monitoring, to determine the risks factors associated with HAdV infection and dissemination, and to
assess whether HAdV loads in stools may be used as surrogate markers for HAdV dissemination. Between September 2010 and
December 2011, out of 72 patients, the cumulative incidence rates at day 100 of HAdV digestive infection, systemic infection and related
disease were 35.9%, 24.0%, and 18.3%, respectively. In multivariate analysis, the risk factors for HAdV digestive and systemic infection
were cord blood and in vitro T-cell depletion. Graft-versus-host disease (GVHD) grade >2 was also associated with systemic infection. In
patients with HAdV digestive shedding, GVHD grade >2 and HAdV load in stools were the only risk factors for systemic infection. The
median peak levels of HAdV in stool were 7.9 and 4.0 log10 copies/mL, respectively, in patients with HAdV systemic infection and in
those without. HAdV monitoring in stools of paediatric HSCT recipients receiving cord blood or in vitro T-cell depleted transplants helps
to predict patients at risk for HAdV systemic infection. Our results provide a rationale for randomized controlled trials to evaluate the
beneﬁt of anti-HAdV pre-emptive treatments based on HAdV DNA levels in stools.
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E-mail: jerome.le-goff@sls.aphp.frIntroductionViral diseases constitute a major cause of morbidity and mor-
tality after haematopoietic stem cell transplantation. WhereasClinical Microbiology and Infection © 2015 European Society of Creactivations of Herpesviridae family viruses are usually well
controlled through effective monitoring and antiviral treat-
ments, human adenovirus (HAdV) infections remain associated
with high morbidity in paediatric haematopoietic stem cell
transplant (HSCT) patients [1].
Although HAdVs do not produce lifelong infections, they
may persist and lead to endogenous reactivations, especially
from the digestive tract in immunocompromised individuals
[2–4]. Paediatric HSCT recipients are more susceptible to
adenovirus infection than are adults. The incidence of HAdVClin Microbiol Infect 2015; 21: 701–709
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.03.011
TABLE 1. Patient characteristics, transplantation modalities,
and outcomes
Parameters Value N Median (IQR) or %
Age at SCT (years) 72 6.5 (3.8–11.6)
Gender Male 42 58.3
Female 30 41.7
Diagnosis AML 9 12.5
ALL 21 29.2
JMML 9 12.5
Lymphoma 5 6.9
Haemoglobinopathy 11 15.3
Others 17 23.6
TBI Yes 22 35.5
Allograft in CR1 Yes 45 62.5
Stem cell source Peripheral blood 5 7.0
Bone marrow 53 73.6
Cord blood 14 19.4
Donor type Geno-identical 24 33.3
Haplo-identical 5 6.9
9/10 HLA-unrelated 29 40.3
4/6 cord blood 14 19.4
Acute GVHD No 31 43.1
Grade 2 10 13.9
Grade >2 25 34.7
Prior death 6 8.3
HAdV digestive infection Yes 28 38.9
HAdV systemic infection Yes 18 25.0
HAdV probable disease Yes 13 18.1
HAdV disease symptoms Fever 10 76.9
Diarrhoea 10 76.9
Respiratory disease 7 53.9
Hepatitis 11 84.6
Encephalitis 3 23.1
Multivisceral failure 1 7.7
Pancreatitis 1 7.7
Haemorrhagic cystitis 2 15.4
Death M3 7 9.7
M12 13 16.7
ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; GVHD, graft-versus-
host disease; HAdV, human adenovirus; HLA, Human Leucocyte Antigen; IQR,
interquartile range; JMML, juvenile myelomonocytic leukaemia; M3, 3 months after
graft; M12, 12 months after graft; SCT, stem cell transplantation; TBI, total body
irradiation.
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up to 6% in adults [3–7].
Treatment options are limited [8]. Cidofovir and ribavirin
are antiviral drugs that are effective in vitro, although their use
has not been validated with randomized trials [4,8,9]. Some
new strategies under clinical investigation have been raising
new hopes. First, CMX001 (brincidofovir), a lipophilic conju-
gate of cidofovir, providing a larger tissue distribution and a
higher intracellular concentration than cidofovir, has shown
encouraging results in a few case reports [10,11]. Second, the
infusion of anti-HAdV T-cells expanded from the donor or
from a third party has been reported to be an effective strat-
egy, provided that the treatment can be initiated quickly to
enable control of viral replication [12,13]. Because early in-
terventions are key to antiviral efﬁcacy [8,13], there is a need,
ﬁrst, to identify patients with a high risk of HAdV disseminated
infection, and second to deﬁne when to initiate pre-emptive or
curative treatment.
In this study, we assessed the risk factors associated with
HAdV digestive shedding, blood infection and HAdV disease in a
single paediatric HSCT centre, and determined whether HAdV
loads in stools and plasma may be used as surrogate markers forClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectHAdV dissemination. In agreement with previous reports
[3,14], the risk factors that we have identiﬁed will make it
possible to target patients requiring a narrow follow-up, and
the HAdV load levels in stools that we have deﬁned may be
used to trigger therapeutic intervention.Patients and methodsPatients
Between September 2010 and December 2011, 72 children (30
females and 42 males) who underwent allogeneic stem cell
transplantation at Robert Debré Hospital (Paris, France) were
prospectively followed for up to 12 months. Patient charac-
teristics and modalities of transplantation are summarized in
Table 1. Details of medical history and clinical follow-up are
given in Doc. S1.
Patients with probable HAdV disease were treated with
cidofovir. If renal function was normal, cidofovir was adminis-
tered at 5 mg/kg once weekly with probenecid. If renal function
was impaired (creatinine level twice the normal level), cidofovir
was administered at 1 mg/kg three times weekly with proben-
ecid. Ribavirin or brincidofovir was given to patients not
responding to cidofovir. Brincidofovir was used only when it
was available for compassionate use. When possible, immuno-
suppressive therapy was tapered. Two patients received spe-
ciﬁc anti-HAdV cytotoxic lymphocytes from either a haplo-
identical related donor or a third-party donor. Cidofovir was
given to some patients who had persistent high HAdV DNA
levels in stools and were considered to be at high risk for
disseminated infection.
Ethics statement
The study was carried out in accordance with the Declaration
of Helsinki. This study was a non-interventional study with no
additional procedures. Biological material and clinical data were
obtained only for standard viral diagnostic according to
physicians’ prescriptions. Data analyses were carried out with
an anonymous database. According to the French Health Public
Law (CSP Art L 1121-1.1), such a protocol is exempt from
informed consent application. The two parents or guardians of
these paediatric patients gave written informed consent to all
aspects of the transplantation procedure and to the use of
medical records for research.
Virus monitoring
Whole blood samples were collected weekly and tested for
cytomegalovirus (CMV) and Epstein–Barr virus by quantitative
PCR. HAdV infections were monitored on a weekly basis by
quantitative PCR in plasma and stool samples until discharge orious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
FIG. 1. Cumulative incidence of human adenovirus (HAdV) digestive
infection, systemic infection and probable disease after human stem cell
transplantation (SCT). The 100-day cumulative incidence rates of HAdV
digestive infection (solid line), systemic infection (dashed line) and
probable disease (dotted line) were 35.9%, 24.4%, and 18.3%,
CMI Feghoul et al. Predicting adenovirus infections in paediatric HSCT 703up to day 100 after transplantation. After discharge, HAdV
monitoring was continued for up to 12 months, including
mainly plasma samples.
Deﬁnitions
Local digestive infections were deﬁned as positive HAdV PCR
in stools, systemic infections as positive HAdV PCR in plasma,
and probable HAdV disease as a systemic infection in asso-
ciation with compatible symptoms, without other identiﬁable
causes, including fever, respiratory diseases, haemorrhagic
cystitis, hepatitis, pancreatitis, meningoencephalitis, multi-
organ failure, and diarrhoea with any of the previous symp-
toms. HAdV-related enteritis without any other symptoms
related to HAdV infection was not included as probable
HAdV disease.
Adenovirus quantiﬁcation in stool and plasma
specimens
The extraction procedures for stool specimens and plasma are
given in Doc. S1. HAdV DNA was quantiﬁed with the Adeno-
virus Rgene kit (Argene, Varhilles, France). The results were
expressed as copies/mL of the stool phosphate-buffered saline
suspension. The threshold for quantiﬁcation was 200 copies/
mL.
Adenovirus typing
HAdV species identiﬁcation was performed with real-time PCR
assays (details are given in Doc. S1) [15]. HAdV type was
determined by sequencing of hypervariable region 7 of the
hexon gene and ﬁbre [16,17].
Statistical analysis
Summary statistics were computed, either medians with
interquartile range (IQRs), or percentages. Cumulative inci-
dence curves of HAdV infection and disease were computed in
a competing-risks framework, wherein death prior to the event
of interest was considered as a competing event. Cause-speciﬁc
Cox models were used to assess the predictive set of covariates
associated with each outcome, with multivariable models
incorporating covariates that were selected by the univariate
analyses at the 10% level; viral loads on log10 scales were
introduced as time-dependent covariates. Cubic smoothing
spline functions in generalized additive models allowed us to
plot the hazard of event along the covariate scale, testing for
non-linearity [18]. Point estimates of cause-speciﬁc hazard ratio
(HR) were reported with 95% CIs.
Statistical analyses were performed with SAS V9.3 (SAS,
Cary, NC, USA) and R 2.13.0 (http://www.R-project.org/)
packages. All tests were two-sided, with p-values of 0.05
denoting statistical signiﬁcance.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyResultsAdenovirus digestive infections, systemic infections,
and disease
The cumulative incidence rates of HAdV digestive infection,
systemic infection and related disease at day 100 following
transplantation were 35.9% (95% CI 34.7–37.1%), 24.0% (95%
CI 23.0–25.0%), and 18.3% (95% CI 17.4–19.2%), respectively
(Fig. 1).
Adenovirus detection in stools
Adenovirus was detected in stools in 28 patients (39%). Of the
28 patients with HAdV intestinal shedding, 21 (75%) had diar-
rhoea, including 13 with a diagnosis of digestive graft-versus-
host disease (GVHD). Viral loads at the ﬁrst detection ranged
from 2.4 log10 to 9.99 log10 copies/mL. The maximal HAdV viral
load in stools was signiﬁcantly higher in patients with diarrhoea
(median 5.5 log10 copies/mL; IQR 3.5–8.0) than in those
without diarrhoea (median 2.5 log10 copies/mL; IQR 2.4–3.3)
(p 0.05). The median duration of HAdV digestive infection was
27 days (IQR 9.5–99). There was a strong predominance of
species C (57%) (Table 2).
Adenovirus systemic infection
HAdV was detected in plasma in 18 patients (25%). One patient
had remained negative for HAdV in stools before the positiverespectively.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
TABLE 2. Viral characteristics of human adenovirus (HAdV)
digestive infections, systemic infections, and related diseases
HAdV digestive
infection
HAdV systemic
infection
Probable HAdV
disease
Number of cases (n) 28 18 13
Minimal viral loada 3.3 (2.7–5.1) 0 (0–0) 0 (0–0)
First viral loada 4.5 (3.4–7.0) 2.7 (2.6–3.1) 2.8 (2.567–3.074)
Maximal viral loada 7.0 (4.0–8.3) 4.4 (3.1–5.4) 4.7 (3.16–5.475)
Species, n (%)
A 5b (18) 3 (17) 2 (15)
B 2 (7) 2 (11) 2 (15)
C 16 (57) 10 (56) 7 (54)
D 1 (3.5) 1 (5.3) 1 (8)
F 1 (3.5) 1 (5.3) 0 (0)
Undetectedc 3 (11) 1 (5.3) 1 (8)
Type, n
A-12 1 1 0
A-31 4b 2 2
B-3 1 0 0
B-11 1 1 1
C-1 3 2 2
C-2 9 6 4
C-5 3 1 1
B undetectedc 0 1 1
C undetetedc 1 1 0
D undetectedc 1 1 1
F-41 1 1 0
aMedian (interquartile range). For HAdV digestive infection, HAdV loads indicated are
those determined in stools, and for HAdV systemic infection and probable HAdV
disease, HAdV loads indicated are those determined in plasma. HAdV loads are
expressed as log10 copies/mL.
bA co-infection with HAdV C2 occurred during the follow-up of a patient infected
with HAdV A31.
cHAdV loads were too low for HAdV typing.
TABLE 3. Univariate analyses of predictive factors for human ad
disease (all variables associated in univariate analyses at the 10%
models
HAdV digestive infection HAdV
In all patients In all p
28 events/72 patients 18 even
Age <6 years 2.4 (1.12–5.14)* 2.3 (0.8
Allograft in CR1 2.0 (0.88–4.55) 2.7 (0.8
Non-geno-identity 3.0 (1.15–7.99)* 5.2 (1.2
Cord blood 4.9 (2.17–11.0)* 3.0 (1.1
Corticosteroidsa 2.9 (1.08–7.55)* 2.8 (0.9
Fludarabineb 1.8 (0.84–3.78) 1.9 (0.7
Endoxanb 0.6 (0.28–1.28) 0.4 (0.1
GVHD grade >2 1.2 (0.55–2.58) 2.6 (1.0
In vitro T-cell depletion 3.7 (1.22–11.0)* 3.6 (1.0
ATG 0.8 (0.36–1.67) 0.7 (0.3
Previous positive HAdV stool — 2.4 (0.8
Previous HAdV systemic infection — —
In patien
15 even
Age <6 years — 1.3 (0.4
Allograft in CR1 — 1.9 (0.5
Non-10/10 HLA pheno-identity — 3.9 (0.5
Cord blood — 1.3 (0.4
Corticosteroidsa — 1.6 (0.5
Fludarabineb — 1.3 (0.4
Endoxanb — 0.3 (0.0
GVHD grade >2 — 5.0 (1.6
In vitro T-cell depletion — 1.8 (0.4
ATG — 0.7 (0.2
Stool HAdV load — 1.4 (1.0
Plasma HAdV load — —
ATG, anti-thymoglobulin; CR1, First Complete Remission; GVHD, graft-versus-host disease;
Hazard ratio (Conﬁdence interval 95%).
aIn preventing GVHD.
bAs conditioning regimen.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdetection in plasma. HAdV viraemia was detected within 6
months for all patients but one, who, 10 months after trans-
plantation, experienced an enteritis episode related to HAdV
type 41. The plasma HAdV load at the ﬁrst detection ranged
from 2.3 log10 to 4.5 log10 copies/mL. The maximal viral load
ranged from 2.42 log10 to 9.75 log10 copies/mL. The median
duration of HAdV systemic infection was 24 days (IQR 14–63).
Species C was the most frequent species associated with vir-
aemia (56%). There was perfect concordance between the
types detected in stools and those detected in plasma. Noso-
comial transmission from a patient infected with an HAdV
species C type 2 to two other patients was suspected (not
shown). If these two cases had been prevented, the prevalence
of HAdV systemic infection in HSCT children would have
decreased from 24% (95% CI 15.5–36.6%) to 22% (95% CI
13.3–33.6%).
Adenovirus disease
Thirteen patients (72%) with HAdV viraemia experienced
HAdV disease, including one who had stool samples negative
for HAdV before the detection in plasma. All occurred before
day 100 after transplantation. The main clinical signs are shownenovirus (HAdV) digestive infection, systemic infection, and
level (indicated by *) were incorporated in the multivariable
systemic infection Probable HAdV disease
atients In all patients
ts/72 patients 13 events/72 patients
9–5.94)* 1.6 (0.54–4.83)
8–8.15)* 1.6 (0.48–5.06)
–22.8)* 3.3 (0.74–15.0)
1–8.04)* 2.6 (0.80–8.46)
3–8.59)* 1.7 (0.37–7.57)
4–4.78) 1.0 (0.31–3.33)
3–0.99)* 0.6 (0.20–1.84)
3–6.56)* 2.8 (0.95–8.43)*
3–12.8)* 3.0 (0.66–13.6)
3–2.18) 1.2 (0.35–3.73)
4–7.10) 1.9 (0.56–6.15)
4.4 (1.20–16.4)*
ts with HAdV digestive infection In patients with HAdV systemic infection
ts/28 patients 13 events/18 patients
6–3.90) 0.7 (0.25–2.21)
2–6.64) 0.5 (0.16–1.78)
1–29.6) 0.5 (0.11–2.35)
7–3.72) 0.8 (0.24–2.59)
2–5.10) 0.4 (0.12–2.47)
6–3.48) 0.5 (0.16–1.70)
9–1.18)* 1.9 (0.60–5.74)
3–15.6)* 1.2 (0.40–3.51)
9–6.28) 0.9 (0.20–4.08)
4–1.84) 1.4 (0.42–4.45)
9–1.79)* 0.9 (0.75–1.03)
1.1 (0.84–1.46)
HLA.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
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signiﬁcantly higher in patients with HAdV disease (median 4.7
log10 copies/mL; IQR 3.16–5.48) than in those without (median
3.5 log10 copies/mL; IQR 3.077–3.813) (p 0.44). However, an
HAdV plasma load of >4 log10 copies/mL was observed in nine
patients with HAdV disease and in one without.
Risk factors for digestive infection, systemic infection,
and HAdV disease
Tables 3 and 4 show the predictive factors for HAdV positivity
in stools, HAdV systemic infection, and HAdV-related disease.
This allowed selection at the 10% level for digestive infection,
young age, non-geno-identity, cord blood transplantation,
corticosteroid use for the prophylactic treatment of GVHD,
and in vitro T-cell depletion. Of those variables, only cord blood
transplantation and in vitro T-cell depletion were signiﬁcantly
associated with outcome, based on a multivariable cause-
speciﬁc Cox model (Table 4).
Among the eight selected predictive factors for systemic
infection in univariate analysis (Table 3), acuteGVHD, cord blood
transplantation and in vitro T-cell depletion were the three
retained in themultivariablemodel (Table 4). Introducing the past
occurrence of HAdV intestinal shedding as a time-dependent
covariate into themultivariable model did not modify this ﬁnding.
The occurrence of GVHD grade >2 and previous HAdV
systemic infection were both associated with HAdV disease at
the 10% level in univariate analyses (Table 3). Only previous
HAdV systemic infection remained predictive for HAdV disease
in the multivariable model (Table 4).
It is of note that the median total lymphocyte count did not
differ between patients with and without HAdV digestive
infection (0.9 × 109/L vs. 1.2 × 109/L; p 0.55), HAdV viraemia
(1.2 × 109/L vs. 0.8 × 109/L, p 0.48), and HAdV-related disease
(1.3 × 109/L vs. 0.9 × 109/L; p 0.22) (Table S1).TABLE 4. Multivariable analysis of predictive factors for
human adenovirus (HAdV) digestive infection, systemic
infection, and disease: results of the ﬁnal model stepwise
selection
Multivariable models HR (95% CI) p
HAdV digestive infection, 28 events/72 patients
Cord blood 6.0 (2.57–14.0) <0.0001
In vitro T-cell depletion 5.8 (1.82–18.3) 0.0029
HAdV systemic infection, 18 events/72 patients
Cord blood 3.8 (1.33–10.9) 0.013
GVHD grade >2 2.8 (1.10–7.20) 0.030
In vitro T-cell depletion 5.3 (1.38–20.3) 0.015
HAdV systemic infection after HAdV digestive infection, 15 events/28 patients
GVHD grade >2 4.5 (1.28–15.6) 0.019
Stool HAdV load 1.4 (1.04–1.74) 0.023
Probale HAdV disease, 13 events/72 patients
Previous HAdV systemic infection 4.4 (1.20–16.4) 0.026
GVHD; graft-versus-host disease; HR, hazard ratio.
Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyIn this population, patients showed other viral reactivations.
Twenty-ﬁve patients showed reactivation of CMV in blood, 43
showed an Epstein–Barr virus infection, nine showed a BK vi-
rus infection, and three showed a human herpesvirus 6 infec-
tion. Only the occurrence of CMV systemic infection was
associated with that of HAdV (11 (61%) in patients with HAdV
systemic infection vs. 14 (26%) in patients without; p 0.01).
Association of HAdV load in stools and blood with
viraemia and disease
When the univariate analyses were restricted to the 28 patients
with intestinal shedding of HAdV, the occurrence of systemic
infection was increased in cases of acute GVHD grade >2, as
well as with the maximal viral load detected in stools, whereas
it was decreased by the use of endoxan in the conditioning
regimen (Table 3). The median peak levels of HAdV in stools
were 7.89 log10 copies/mL (IQR 6.96–9.31) and 4.03 log10
copies/mL (IQR 3.78–5.54), respectively, in the 15 patients
who experienced HAdV systemic infection and in those 13 who
did not (p 0.003). Fig. 2 shows how the maximal HAdV load in
stools may predict infection, demonstrating that the higher the
viral load, the higher the risk of infection. In a multivariable Cox
model, only the viral load in stools (p 0.023) and the occur-
rence of GVHD grade >2 (p 0.02) were associated with the
occurrence of systemic infection in patients with intestinalFIG. 2. Estimation of the risk of human adenovirus (HAdV) viraemia as
a function of the HAdV viral load in stools, by the use of smoothing
splines; estimation of how the maximal value of HAdV viral load in
stools modiﬁes the risk of HAdV viraemia from generalized additive
models. For each of the 28 patients with HAdV digestive infection, the
value of the maximal HAdV load detected in stools is indicated on the x-
axis with a vertical dash, and expressed in log10 copies/mL.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
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acteristic curve for all possible cut-offs, with an estimated area
under the curve of 0.83. This illustrates the discriminative ca-
pacity of such a measure to distinguish between the presence
and absence of systemic infection. At a threshold of 5 log10
copies/mL HAdV in stools, the sensitivity and speciﬁcity for
detecting a systemic infection in patients with HAdV intestinal
shedding were 93.3% and 61.5%, respectively.
When the analysis was restricted to the 18 patients with
HAdV viraemia, no factors allowed prediction of the occur-
rence of disseminated disease (Table 3).
Antiviral treatment
All patients with HAdV-related disease received antiviral treat-
ment. Eleven patients received one to eight injections of cido-
fovir. Following cidofovir treatment, two patients also received
ribavirin, four received brincidofovir, and one received ribavirin
and then brincidofovir. Two patients also received anti-HAdV
cytotoxic lymphocytes. Of these 11 patients, six died from
HAdV-related disease. Two patients received only CMX001.
Both died, including one because of an HAdV-related disease.
Four patients received two to ﬁve injections of cidofovir
because they had HAdV digestive infection with high HAdV
DNA levels, and were considered to be at high risk for
disseminated infection. One patient with persistent high HAdV
DNA levels in stools despite cidofovir treatment received
brincidofovir. Each of these four patients eventually cleared the
HAdV infections, and none had HAdV viraemia.1 – Sp (%)
Se
 
(%
)
0 20 40 60 80 100
0
20
40
60
80
100
Threshold = 9.20
Threshold = 5.48
Threshold = 7.27
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FIG. 3. Receiver operating characteristic curves showing sensitivity
(Se) vs. 1 – speciﬁcity (Sp) for the prediction of human adenovirus
(HAdV) disease with different positive cut-off values for HAdV load in
stools.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectAdenovirus-related and transplant-related mortality
Of the 72 patients studied, 13 died (18%) within 1 year after
transplantation. The deaths were attributed to HAdV in seven,
relapse in three, Pseudomonas aeruginosa septicaemia in two,
and respiratory failure in one. Of the 13 patients with HAdV-
related disease, eight died, including seven whose deaths were
attributed to HAdV, and one whose death was attributed to
respiratory failure without HAdV respiratory infection. CMV
infection (HR 8.1, 95% CI 1.03–63.0) and the use of ﬂudarabine
(HR 5.0, 95% CI 1.49–16.6) and melphalan (HR 4.3, 95% CI
1.36–13.6) in the conditioning regimen were identiﬁed as
baseline prognostic factors in univariate analyses of overall
survival. Additionally, the risk of death in patients who expe-
rienced HAdV systemic infection was signiﬁcantly increased as
compared with patients who remained negative for HAdV in
plasma (HR 9.5, 95% CI 2.77–32.5; p 0.0003). Otherwise, the
risk of death was decreased in cases of anti-thymoglobulin use
(HR 0.3, 95% CI 0.09–0.93; p 0.037) but increased in cases of
in vitro T-cell depletion (HR 8.9, 95% CI 2.57–30.7; p 0.0006).
Besides HAdV infection (HR 11.4, 95% CI 2.53–51.7; p 0.0015),
multivariable analysis retained only the use of ﬂudarabine (HR
8.30, 95% CI 2.07–33.2; p 0.0028) and CMV infection (HR 13.5,
95% CI 1.56–116.4; p 0.018) as adding prognostic information
to each other.DiscussionIn our series, during the ﬁrst 100 days following transplantation,
the incidence rates of HAdV digestive infection, systemic
infection and HAdV-related disease were 35.9%, 24.0%, and
18.3%, respectively. Our data agree with previous studies
conducted in paediatric HSCT patients, and conﬁrm that HAdV
infections are common in paediatric HSCT patients [3,4,7,14].
Another recent study found an even higher frequency of HAdV
systemic infection in paediatric HSCT patients (50.4%), despite
a similar rate of HAdV disease (11.3%) [19].
We have reported the following main risk factors: cord
blood and in vitro T-cell depletion for HAdV digestive infection;
cord blood, GVHD grade >2 and in vitro T-cell depletion for
HAdV systemic infection; and HAdV viraemia for probable
HAdV disease. Our results conﬁrm the association between the
occurrence of HAdV replication and cord blood trans-
plantation, severe GVHD, and in vitro T-cell depletion [3,4].
Therefore, patients receiving cord blood transplants or in vitro
T-cell-depleted transplants, and those presenting with severe
GVHD, should beneﬁt from weekly molecular detection of
HAdV within the ﬁrst 100 days following transplantation.
In contrast to some other studies, our multivariable analysis
did not show unrelated donors, or lymphopenia, as risk factorsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
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thymoglobulin was not predictive of HAdV infection or dis-
ease. Several studies have reported discordant results regarding
in vivo T-cell depletion after reduced-intensity conditioning with
alemtuzumab or ex vivo T-cell depletion of the graft [19–24]. In
a series of 238 paediatric patients, Mynarek et al. found that high
blood HAdV loads were restricted to patients who received T-
cell depletion therapy [19]. Chakrabati et al. have shown that
the absolute lymphocyte count at 90 to 120 days had a strong
impact on HAdV infections in patients who had received
alemtuzumab [21]. A recent retrospective analysis of a 2879-
patient cohort showed that the frequency of patients with
HAdV-disseminated infections was higher when absolute
lymphocyte counts were <200/mm3 [24].
Altogether, these data may suggest that T-cell depletion
therapy is not itself a trigger of HAdV replication, but that, once
HAdV infection occurs, the T-cell depletion may contribute to
the spread of infection, because the T-cell speciﬁc immune
response does not recover. Assessment of the speciﬁc anti-
HAdV cellular response could be complementary to HAdV
loads for predicting either systemic infection or related disease.
We identiﬁed various species in stool and plasma samples.
Species C HAdVs were the most frequent in digestive in-
fections, in systemic infections, and in related diseases, as
shown in other studies [3,14]. However, species C seems not
to be associated with higher pathogenicity, as the ratio between
species C and the others species remained the same in HAdV
digestive infections, systemic infections, and related disease.
The higher frequency of species C than of other species
detected in paediatric transplant patients reﬂects their ability to
persist frequently in the digestive tract [25,26]. Species A,
which is also associated with digestive infections, was the sec-
ond most frequent species that we found. As most HAdV in-
fections occurred early after transplantation, the most likely
mechanism of digestive infection after transplantation is reac-
tivation rather than new infection. Whether the detection of
HAdV in the digestive tract before transplantation would pre-
dict post-transplant infection and could help to determine
which patients would require HAdV monitoring is an area for
further study.
In our study, all patients but one who experienced systemic
HAdV infection had the virus detectable in stool specimens.
This conﬁrms that the intestinal tract is a common source of
virus dissemination [14,26]. When restricting the analysis to the
patients with intestinal shedding of HAdV, we found a signiﬁcant
difference in median peak levels of HAdV in stools (>3.5 log10)
between patients who experienced HAdV systemic infection
and those who did not. GVHD grade >2 and HAdV in stools
were the only factors associated with the occurrence of sys-
temic infection in a multivariable Cox model. In addition, weClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyshowed that the risk of viraemia remained limited for HAdV
loads in stools of <5 log10 copies/mL. In contrast, HAdV vir-
aemia level did not add any prognostic information to that
provided by the viral load in stools with regard to the risk of
progression to HAdV disease.
Our data corroborate those published by Lion et al. They
showed an incidence of HAdV viraemia of 73% in patients with
a peak of virus levels of >6 log10 copies per gram of stool vs. 0%
in patients with HAdV levels below this threshold [14]. Jeulin
et al. also found that an HAdV DNA level of >5.47 log10 copies
per gram of stool preceded HAdV DNA detection in blood
[27]. In contrast, Mynarek et al. recently reported a higher rate
of HAdV blood infections (50.4%) than of digestive infections
(43.2%) [19]. The higher incidence of viraemia in that study may
be explained by the use of whole blood instead of plasma. The
lack of standardization of methods for the quantiﬁcation of
HAdV in stool may also account for some apparent
discrepancies.
Altogether, these results thus suggest that quantitative
monitoring of HAdV DNA in stool samples could allow the
prediction of imminent viraemia in paediatric HSCT patients
with risk factors for HAdV systemic infection, and could be
used to trigger pre-emptive treatment to control HAdV repli-
cation in the digestive tract and to prevent systemic spread of
the infection.
Whereas the low concentration of cidofovir in the digestive
tract does not enable such a goal to be achieved, CMX001
(brincidofovir), which provides a high tissue concentration, may
make this objective more attainable [10,28,29]. The results of a
phase 2 study—a randomized, double-blind, placebo-controlled
trial evaluating the safety and efﬁcacy of CMX001 for the
prevention of HAdV disease in HSCT recipients with asymp-
tomatic HAdV viraemia (ADV HALT Trial, NCT01241344)—
are pending. Diarrhoea has been reported as the most frequent
adverse event [30]. Because diarrhoea is a sign of either in-
fectious enteritis or GVHD, avoiding or reducing such an
adverse effect is desirable. A pre-emptive treatment targeting
HAdV digestive replication before the onset of viraemia could
reduce the risk of dissemination with shorter treatment dura-
tion, thus reducing drug exposure and possibly the risk of
digestive adverse events.
Despite the use of antiviral drugs, including brincidofovir, and
immunotherapy, the mortality rate of patients with HAdV-
related disease was high (61.5%, 8/13), most deaths being
related to HAdV infection. We may assume that the interven-
tion was too late for speciﬁc antiviral activity to be translated
into clinical efﬁcacy. It is of note that four patients received
antiviral drugs (cidofovir and brincidofovir) for HAdV digestive
infection with rapidly increasing HAdV levels in stools, and none
developed HAdV systemic infection.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 701–709
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subpopulations as being at the greatest risk for HAdV dissem-
inated infection that might warrant HAdV molecular screening,
and has shown that HAdV DNA levels in stools are predictive
of disseminated infection in high-risk patients. On the basis of
cumulative data [14,27], we recommend HAdV stool moni-
toring for paediatric HSCT recipients receiving cord blood
transplants or in vitro T-cell-depleted transplants, and for pa-
tients with severe GVHD. Our results, together with previous
reports [14,27], provide a rationale for conducting randomized
clinical trials to evaluate the beneﬁt of anti-HAdV pre-emptive
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